| Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia (NCT07686263) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2026-09-03 |
| Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers (NCT07681076) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2026-08-03 |
| A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively (NCT07424404) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2026-04-07 |
| KarXT Concentrations in the Breast Milk and Plasma of Lactating Females (NCT07257120) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2026-01-09 |
| A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants (NCT07204418) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2025-10-13 |
| A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin (NCT07118215) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2025-09-29 |
| A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants (NCT06729970) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2024-12-26 |
| Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia (NCT06572449) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2024-10-28 |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants (NCT06605950) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2024-10-01 |
| A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) (NCT06585787) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2024-09-26 |
| A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) (NCT06126224) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2023-08-28 |
| Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) (NCT05980949) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2023-07-11 |
| A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia (NCT05919823) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2023-05-29 |
| An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia (NCT05643170) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2022-11-08 |
| A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) (NCT05511363) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2022-08-23 |
| An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (NCT05304767) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2022-03-07 |
| A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (NCT05145413) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2021-11-12 |
| An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5) (NCT04820309) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2021-06-02 |
| A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3) (NCT04738123) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2021-04-06 |
| An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4) (NCT04659174) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2021-02-01 |
| A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2) (NCT04659161) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2020-12-16 |
| A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia (NCT03697252) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2018-09-18 |
| Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium (NCT02831231) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 2016-09-07 |